# Pulmonary arterial hypertension

Condition · id `cardio:pulmonary-arterial-hypertension` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: PAH

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Pulmonary arterial hypertension, or PAH, is one type of pulmonary hypertension. MeSH describes it as a progressive, rare lung disease marked by high blood pressure in the pulmonary artery. NHLBI lists it as the first of five groups of pulmonary hypertension and says that worldwide over half of cases have no known cause.

## Technical summary

MeSH D000081029 is named Pulmonary Arterial Hypertension; its scope note describes a progressive rare pulmonary disease characterized by high blood pressure in the pulmonary artery. MedlinePlus says the types of pulmonary hypertension are based on what caused the disease.

## Claims, with the population each applies to

## Context: People with deep vein thrombosis, pulmonary embolism, peripheral artery disease or pulmonary hypertension, as described in MedlinePlus and NHLBI patient pages

Recipient: Recipient not specified; Population: People with the condition each page covers. The pages give no age limits and no inclusion criteria.; Care setting: Not stated; patient information pages; Geography: Not stated; United States federal health agencies (NLM and NIH); Life stage: Not stated on the pages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive pages)

### MeSH describes pulmonary arterial hypertension as a progressive, rare lung disease marked by high blood pressure in the pulmonary artery. MedlinePlus lists it as one type of pulmonary hypertension, and says the types are based on what caused the disease. NHLBI lists it as the first of five groups of pulmonary hypertension and says that worldwide over half of cases have no known cause.

- Category: Description
- Evidence stage: Evidence stage unknown
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: People with the condition each page covers. The pages give no age limits and no inclusion criteria.; Care setting: Not stated; patient information pages; Geography: Not stated; United States federal health agencies (NLM and NIH); Life stage: Not stated on the pages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive pages)
- Limitations: Patient-education pages from US government sources. They give no study, no size of risk and no population, and they do not say how often any of this happens. The NHLBI proportion is a worldwide figure that the page does not source.
- Last checked: 2026-10-30
- Sources:
  1. Supports: MeSH scope note for descriptor D000081029 (Pulmonary Arterial Hypertension) (Dataset, edition MeSH linked-data record of the preferred concept M000649540 of descriptor D000081029, fetched 2026-10-30. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M000649540>
     Locator: scopeNote.@value. Retrieved 2026-10-30T19:43:32Z. Source state: Current. Version fingerprint: 0d86e2a395a34cb0e3eaf9ab19c77e0acee1f2208e7d2c0004f7dc5c13ac4074.
     How it applies: MeSH scope note.
  2. Supports: Pulmonary Hypertension (MedlinePlus health topic) (Webpage, edition Page fetched 2026-10-30. The page shows a last-updated date in its footer; it is not used here.) <https://medlineplus.gov/pulmonaryhypertension.html>
     Locator: What is pulmonary hypertension?, paragraph 4, sentence 1. Retrieved 2026-10-30T19:44:13Z. Source state: Current. Version fingerprint: 25f50e785cf52e29bca0ff8871800a088148f9f83265f6b327951b83f37a0fda.
     How it applies: MedlinePlus: PAH is one type.
  3. Supports: Pulmonary Hypertension (MedlinePlus health topic) (Webpage, edition Page fetched 2026-10-30. The page shows a last-updated date in its footer; it is not used here.) <https://medlineplus.gov/pulmonaryhypertension.html>
     Locator: What is pulmonary hypertension?, paragraph 4, sentence 2. Retrieved 2026-10-30T19:44:13Z. Source state: Current. Version fingerprint: 25f50e785cf52e29bca0ff8871800a088148f9f83265f6b327951b83f37a0fda.
     How it applies: MedlinePlus: types are based on cause.
  4. Supports: Pulmonary Hypertension: What Is Pulmonary Hypertension? (NHLBI) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated on May 01, 2023.) <https://www.nhlbi.nih.gov/health/pulmonary-hypertension>
     Locator: What Is Pulmonary Hypertension?, group list item 1. Retrieved 2026-10-30T19:45:22Z. Source state: Current. Version fingerprint: 98fd71a76fdb8f2f17300792080a72f854e2b80953ac5c23501dcf46efa92b8b.
     How it applies: NHLBI: group 1 of five. Last updated May 01, 2023 according to the page.
  5. Supports: Pulmonary Hypertension: What Is Pulmonary Hypertension? (NHLBI) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated on May 01, 2023.) <https://www.nhlbi.nih.gov/health/pulmonary-hypertension>
     Locator: What Is Pulmonary Hypertension?, paragraph 3. Retrieved 2026-10-30T19:45:22Z. Source state: Current. Version fingerprint: 98fd71a76fdb8f2f17300792080a72f854e2b80953ac5c23501dcf46efa92b8b.
     How it applies: NHLBI: over half of cases have no known cause.

## Connected pages

- One type of pulmonary hypertension: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Filed under this front: Medicines (`cardio:front-medicines`)
- Related to: Eisenmenger syndrome (`cardio:eisenmenger-syndrome`)
- Related to: Patent ductus arteriosus (`cardio:patent-ductus-arteriosus`)
- Related to: Activin signaling inhibitors (`cardio:activin-signaling-inhibitors`)
- Evaluated for this: Ambrisentan (`cardio:ambrisentan`) [a claim, not a settled fact; see claim `cardio:claim-fda-letairis-label-indications` and its context]
- Evaluated for this: Bosentan (`cardio:bosentan`) [a claim, not a settled fact; see claim `cardio:claim-fda-tracleer-label-indications` and its context]
- Evaluated for this: Bosentan (`cardio:bosentan`) [a claim, not a settled fact; see claim `cardio:claim-fda-tracleer-label-paediatric` and its context]
- Related to: Endothelin receptor antagonists (`cardio:endothelin-receptor-antagonists`)
- Evaluated for this: Macitentan (`cardio:macitentan`) [a claim, not a settled fact; see claim `cardio:claim-fda-opsumit-label-indications` and its context]
- Related to: PDE5 inhibitors for pulmonary hypertension (`cardio:pde5-inhibitors-for-pulmonary-hypertension`)
- Related to: Prostacyclin pathway drugs (`cardio:prostacyclin-pathway-drugs`)
- Evaluated for this: Riociguat (`cardio:riociguat`) [a claim, not a settled fact; see claim `cardio:claim-fda-adempas-label-indications` and its context]
- Evaluated for this: Selexipag (`cardio:selexipag`) [a claim, not a settled fact; see claim `cardio:claim-fda-uptravi-label-indications` and its context]
- Evaluated for this: Selexipag (`cardio:selexipag`) [a claim, not a settled fact; see claim `cardio:claim-fda-uptravi-label-paediatric` and its context]
- Evaluated for this: Sildenafil (`cardio:sildenafil`) [a claim, not a settled fact; see claim `cardio:claim-fda-revatio-label-indications` and its context]
- Evaluated for this: Sildenafil (`cardio:sildenafil`) [a claim, not a settled fact; see claim `cardio:claim-fda-revatio-label-paediatric` and its context]
- Related to: Soluble guanylate cyclase stimulators (`cardio:soluble-guanylate-cyclase-stimulators`)
- Evaluated for this: Sotatercept (`cardio:sotatercept`) [a claim, not a settled fact; see claim `cardio:claim-fda-winrevair-label-indications` and its context]
- Evaluated for this: Tadalafil (`cardio:tadalafil`) [a claim, not a settled fact; see claim `cardio:claim-fda-adcirca-label-indications` and its context]
- Evaluated for this: Treprostinil (`cardio:treprostinil`) [a claim, not a settled fact; see claim `cardio:claim-fda-remodulin-label-indications` and its context]
- Evaluated for this: Treprostinil (`cardio:treprostinil`) [a claim, not a settled fact; see claim `cardio:claim-fda-remodulin-label-transition` and its context]
- Evaluated for this: Treprostinil (`cardio:treprostinil`) [a claim, not a settled fact; see claim `cardio:claim-fda-tyvaso-label-pah` and its context]
- Evaluated for this: Treprostinil (`cardio:treprostinil`) [a claim, not a settled fact; see claim `cardio:claim-fda-orenitram-label-pah` and its context]

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 60 registry trials

## Provenance

Content hash: cfb4d9b6f163215c45cf543ed360d8de01740a4d48363738515887bc885d6721
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
